CagriSema is a fixed-dose combination of two medications in a single once-weekly injection: cagrilintide (2.4 mg), a long-acting amylin analog, and semaglutide (2.4 mg), the same GLP-1 receptor agonist found in Wegovy and Ozempic
Because the bulk of published research investigating these two compounds in combination has used roughly equal proportions, and because there's no strong mechanistic reason to weight angiogenesis (BPC-157) over cell migration (TB-500) in tissue-repair research
TB-500 receives attention for cellular migration, connective tissue remodeling, and regenerative physiology
But the vial does not say whether it contains CJC-1295 with DAC or without DAC, and that distinction changes everything about how you dose it
Most peptides reconstitute with standard BAC water
Different mechanisms, different costs, different evidence bases